Drug name - Xpovio

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Sep, 2032

(9 years from now)

US10519139 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(12 years from now)

CN103874690A KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN103842340B KARYOPHARM THERAPS Nuclear Transport Modulatiors And Uses Thereof
Jul, 2032

(9 years from now)

CN106083827A KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN106083827B KARYOPHARM THERAPS Nuclear Transport Modulators And Use Of Hydrazide-Containing
Jul, 2032

(9 years from now)

CN103842340A KARYOPHARM THERAPS Nuclear Transport Modulatiors And Uses Thereof
Jul, 2032

(9 years from now)

CN103874690B KARYOPHARM THERAPS Transport Regulator And Use Thereof Containing A Hydrazide
Jul, 2032

(9 years from now)

CN107072992B KARYOPHARM THERAPS Polymorphs Of
Aug, 2035

(12 years from now)

CN107072992A KARYOPHARM THERAPS Polymorph
Aug, 2035

(12 years from now)

IN361872B KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

IN201401189P1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736883A1 KARYOPHARM THERAPS Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736883B1 KARYOPHARM THERAPS Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736887B1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP2736887A1 KARYOPHARM THERAPS Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Jul, 2032

(9 years from now)

EP3180331B1 KARYOPHARM THERAPS Polymorphs Of Selinexor
Aug, 2035

(12 years from now)

EP3180331A1 KARYOPHARM THERAPS Polymorphs Of Selinexor
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof Jul, 2032

(9 years from now)

Drugs and Companies using SELINEXOR ingredient

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.